raloxifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives	2351	84449-90-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: raloxifene keoxifene raloxifene hydrochloride evista raloxifene HCl	A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. Molecular weight: 473.59 Formula: C28H27NO4S CLOGP: 6.86 LIPINSKI: 1 HAC: 5 HDO: 2 TPSA: 70 ALOGS: -5.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

raloxifene
keoxifene
raloxifene hydrochloride
evista
raloxifene HCl

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Molecular weight: 473.59
Formula: C28H27NO4S
CLOGP: 6.86
LIPINSKI: 1
HAC: 5
HDO: 2
TPSA: 70
ALOGS: -5.97
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	21.12 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	10.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 5, 1998	EMA	ELI LILLY NEDERLAND B.V.
Dec. 9, 1997	FDA	LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endometrial cancer	256.13	12.17	77	20265	3148	63465532
Breast cancer	236.54	12.17	163	20179	48220	63420460
Deep vein thrombosis	171.10	12.17	170	20172	83630	63385050
Retinal vein thrombosis	143.67	12.17	33	20309	457	63468223
Bone density decreased	137.84	12.17	75	20267	14537	63454143
Pulmonary embolism	136.08	12.17	177	20165	116507	63352173
Fracture	114.99	12.17	74	20268	19510	63449170
Femur fracture	110.70	12.17	98	20244	41658	63427022
Spinal compression fracture	104.25	12.17	62	20280	14221	63454459
Retinal vein occlusion	84.02	12.17	30	20312	2113	63466567
Hip fracture	81.77	12.17	71	20271	29403	63439277
Transient ischaemic attack	72.22	12.17	74	20268	37679	63431001
Body height decreased	71.60	12.17	43	20299	10035	63458645
Cerebral infarction	71.26	12.17	60	20282	23833	63444847
Fall	70.53	12.17	280	20062	392054	63076626
Thoracic vertebral fracture	68.04	12.17	32	20310	4560	63464120
Compression fracture	66.13	12.17	35	20307	6413	63462267
Pelvic fracture	65.22	12.17	45	20297	13303	63455377
Drug ineffective	63.58	12.17	152	20190	1044613	62424067
Breast cancer in situ	62.50	12.17	22	20320	1486	63467194
Breast cancer female	62.26	12.17	44	20298	13515	63455165
Lumbar vertebral fracture	58.07	12.17	31	20311	5779	63462901
Cerebrovascular accident	57.86	12.17	115	20227	107909	63360771
Oestrogen receptor assay positive	57.45	12.17	16	20326	496	63468184
Spinal fracture	56.80	12.17	47	20295	18224	63450456
Visual acuity reduced	53.43	12.17	49	20293	21777	63446903
Osteonecrosis of jaw	53.42	12.17	61	20281	35062	63433618
Off label use	53.16	12.17	84	20258	674378	62794302
Infusion related reaction	50.27	12.17	9	20333	245512	63223168
Product use issue	49.96	12.17	6	20336	220514	63248166
Toxicity to various agents	48.64	12.17	10	20332	247240	63221440
Low turnover osteopathy	46.59	12.17	24	20318	4161	63464519
Systemic lupus erythematosus	44.22	12.17	7	20335	208911	63259769
Ovarian cancer	43.75	12.17	26	20316	5950	63462730
Osteonecrosis	43.17	12.17	46	20296	24484	63444196
Synovitis	42.55	12.17	5	20337	186913	63281767
Endometrial cancer stage I	42.51	12.17	11	20331	256	63468424
Wrist fracture	42.33	12.17	35	20307	13552	63455128
Postmenopausal haemorrhage	41.50	12.17	18	20324	2124	63466556
Hot flush	41.00	12.17	65	20277	51094	63417586
Muscle spasms	40.55	12.17	126	20216	156024	63312656
Glossodynia	40.18	12.17	5	20337	178871	63289809
Treatment failure	39.24	12.17	8	20334	199035	63269645
Product complaint	37.84	12.17	32	20310	12777	63455903
Myocardial infarction	37.23	12.17	92	20250	99801	63368879
Drug intolerance	36.97	12.17	27	20315	308634	63160046
Retinal vascular thrombosis	36.17	12.17	9	20333	178	63468502
Uterine cancer	35.72	12.17	21	20321	4712	63463968
Blindness unilateral	35.19	12.17	23	20319	6218	63462462
Rheumatoid arthritis	33.36	12.17	20	20322	253799	63214881
Uterine polyp	32.59	12.17	15	20327	2035	63466645
Cataract	32.05	12.17	62	20280	56991	63411689
Alopecia	30.52	12.17	38	20304	337498	63131182
Therapeutic product effect decreased	30.27	12.17	12	20330	193175	63275505
Oedema peripheral	29.80	12.17	130	20212	189381	63279299
Endometrial cancer stage II	28.83	12.17	5	20337	13	63468667
Pericarditis	28.77	12.17	4	20338	131575	63337105
Multiple fractures	28.53	12.17	23	20319	8595	63460085
Hyperlipidaemia	28.09	12.17	33	20309	19538	63449142
Stress fracture	27.96	12.17	22	20320	7941	63460739
Intentional product use issue	27.70	12.17	4	20338	127888	63340792
Rib fracture	27.41	12.17	35	20307	22562	63446118
Retinal haemorrhage	27.26	12.17	18	20324	4951	63463729
Therapeutic product effect incomplete	26.88	12.17	4	20338	125052	63343628
Intestinal pseudo-obstruction	25.62	12.17	10	20332	902	63467778
Lumbar spinal stenosis	25.32	12.17	17	20325	4805	63463875
Lower respiratory tract infection	24.69	12.17	6	20336	132301	63336379
Back pain	24.16	12.17	156	20186	263989	63204691
Injection site haemorrhage	23.91	12.17	34	20308	24280	63444400
Embolism	23.87	12.17	20	20322	7886	63460794
Joint swelling	22.81	12.17	44	20298	327622	63141058
Wound	22.68	12.17	12	20330	163251	63305429
Femoral neck fracture	22.56	12.17	20	20322	8503	63460177
Hepatic enzyme increased	22.56	12.17	19	20323	202309	63266371
Ischaemic stroke	22.07	12.17	28	20314	17929	63450751
Breast cancer recurrent	22.07	12.17	15	20327	4326	63464354
Swelling	21.88	12.17	34	20308	275344	63193336
Thrombosis	21.39	12.17	57	20285	64698	63403982
Embolism venous	21.22	12.17	13	20329	3141	63465539
General physical health deterioration	21.15	12.17	20	20322	201382	63267298
Oestrogen receptor assay negative	21.14	12.17	3	20339	0	63468680
Pain	21.09	12.17	145	20197	740483	62728197
Product use in unapproved indication	20.99	12.17	16	20326	179064	63289616
Peripheral swelling	20.97	12.17	33	20309	265909	63202771
Dementia Alzheimer's type	20.84	12.17	9	20333	1051	63467629
Intramedullary rod insertion	20.30	12.17	11	20331	2112	63466568
Diverticulum	20.24	12.17	22	20320	11969	63456711
Bone pain	20.00	12.17	50	20292	54591	63414089
Osteopenia	19.94	12.17	28	20314	19757	63448923
Fibrocystic breast disease	19.82	12.17	9	20333	1183	63467497
Feeling abnormal	19.77	12.17	97	20245	148295	63320385
Spinal osteoarthritis	19.52	12.17	25	20317	16161	63452519
Psoriatic arthropathy	19.50	12.17	3	20339	91517	63377163
Uterine leiomyoma	19.36	12.17	19	20323	9179	63459501
Endometrial hyperplasia	19.05	12.17	8	20334	872	63467808
Infection	18.48	12.17	28	20314	229145	63239535
Fractured sacrum	18.05	12.17	10	20332	2006	63466674
Humerus fracture	18.00	12.17	18	20324	8898	63459782
Helicobacter infection	17.72	12.17	4	20338	92781	63375899
Blood calcium increased	17.28	12.17	18	20324	9332	63459348
Colitis ischaemic	16.96	12.17	19	20323	10689	63457991
Fracture nonunion	16.84	12.17	10	20332	2285	63466395
Coronary artery disease	16.75	12.17	34	20308	32343	63436337
Colon cancer	16.46	12.17	18	20324	9860	63458820
Musculoskeletal stiffness	16.44	12.17	21	20321	184597	63284083
Intervertebral disc protrusion	16.13	12.17	28	20314	23681	63444999
Foot fracture	15.96	12.17	28	20314	23886	63444794
Kyphosis	15.90	12.17	10	20332	2530	63466150
Insulinoma	15.89	12.17	4	20338	83	63468597
Thrombotic stroke	15.56	12.17	6	20336	524	63468156
Breast swelling	15.47	12.17	8	20334	1398	63467282
Pleurisy	15.31	12.17	16	20326	8324	63460356
Vision blurred	15.15	12.17	64	20278	91860	63376820
Jaw disorder	15.06	12.17	13	20329	5336	63463344
Radius fracture	14.87	12.17	11	20331	3624	63465056
Endometrial hypertrophy	14.59	12.17	5	20337	312	63468368
Gastrooesophageal reflux disease	14.55	12.17	65	20277	95574	63373106
Pathological fracture	14.55	12.17	16	20326	8818	63459862
Haemorrhage subcutaneous	14.44	12.17	10	20332	2973	63465707
Lung neoplasm malignant	14.44	12.17	24	20318	19609	63449071
Erythema multiforme	14.35	12.17	17	20325	10152	63458528
Gastrointestinal tract adenoma	14.27	12.17	5	20337	333	63468347
Osteomyelitis	14.27	12.17	28	20314	25992	63442688
Bone disorder	14.27	12.17	25	20317	21301	63447379
Drug abuse	14.10	12.17	3	20339	72515	63396165
Subacute hepatic failure	14.07	12.17	4	20338	134	63468546
Glaucoma	13.75	12.17	23	20319	18882	63449798
Atrophic vulvovaginitis	13.75	12.17	8	20334	1760	63466920
Altered state of consciousness	13.65	12.17	27	20315	25203	63443477
Sarcoma uterus	13.53	12.17	3	20339	35	63468645
Tibia fracture	13.52	12.17	12	20330	5108	63463572
Abdominal discomfort	13.46	12.17	55	20287	320830	63147850
Breast calcifications	13.28	12.17	7	20335	1271	63467409
Exostosis of jaw	13.23	12.17	7	20335	1282	63467398
Visual field defect	12.79	12.17	13	20329	6548	63462132
Ligament sprain	12.73	12.17	18	20324	12782	63455898
Intentional overdose	12.64	12.17	4	20338	74148	63394532
Atrial fibrillation	12.62	12.17	72	20270	116564	63352116
Intervertebral disc degeneration	12.61	12.17	20	20322	15712	63452968
Vascular headache	12.54	12.17	3	20339	50	63468630
Osteoporotic fracture	12.40	12.17	10	20332	3736	63464944
Acute myocardial infarction	12.40	12.17	30	20312	32094	63436586
Hypersensitivity	12.38	12.17	50	20292	292635	63176045
Aortic aneurysm	12.18	12.17	10	20332	3834	63464846

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endometrial cancer	160.54	13.04	43	14509	2051	79727785
Bone density decreased	125.25	13.04	57	14495	13290	79716546
Breast cancer	111.28	13.04	72	14480	33709	79696127
Retinal vein thrombosis	107.60	13.04	25	14527	660	79729176
Deep vein thrombosis	105.61	13.04	120	14432	120799	79609037
Spinal compression fracture	97.90	13.04	52	14500	16906	79712930
Femur fracture	82.11	13.04	63	14489	38589	79691247
Thoracic vertebral fracture	81.25	13.04	32	14520	5221	79724615
Pulmonary embolism	76.85	13.04	123	14429	171531	79558305
Oestrogen receptor assay positive	73.39	13.04	16	14536	314	79729522
Body height decreased	72.26	13.04	34	14518	8546	79721290
Fracture	68.20	13.04	45	14507	21756	79708080
Breast cancer female	62.94	13.04	34	14518	11427	79718409
Hip fracture	60.69	13.04	48	14504	30713	79699123
Lumbar vertebral fracture	56.60	13.04	27	14525	6995	79722841
Transient ischaemic attack	54.13	13.04	57	14495	52638	79677198
Retinal vein occlusion	54.06	13.04	21	14531	3302	79726534
Pelvic fracture	52.89	13.04	31	14521	12173	79717663
Endometrial cancer stage I	51.89	13.04	11	14541	188	79729648
Spinal fracture	51.04	13.04	35	14517	18019	79711817
Compression fracture	49.52	13.04	24	14528	6436	79723400
Fall	48.95	13.04	197	14355	487432	79242404
Toxicity to various agents	48.77	13.04	9	14543	421531	79308305
Wrist fracture	48.31	13.04	29	14523	11892	79717944
Off label use	46.07	13.04	59	14493	907156	78822680
Breast cancer in situ	43.36	13.04	13	14539	933	79728903
Product complaint	42.83	13.04	28	14524	13321	79716515
Visual acuity reduced	41.72	13.04	38	14514	29431	79700405
Cerebrovascular accident	41.32	13.04	89	14463	155203	79574633
Postmenopausal haemorrhage	40.90	13.04	14	14538	1538	79728298
Hot flush	37.29	13.04	48	14504	54829	79675007
Multiple fractures	36.40	13.04	21	14531	8005	79721831
Muscle spasms	35.39	13.04	90	14462	174640	79555196
Osteonecrosis of jaw	34.50	13.04	41	14511	43185	79686651
Ovarian cancer	34.39	13.04	16	14536	3918	79725918
Endometrial cancer stage II	33.67	13.04	5	14547	7	79729829
Uterine polyp	33.01	13.04	12	14540	1572	79728264
Injection site haemorrhage	31.97	13.04	32	14520	27838	79701998
Osteonecrosis	30.80	13.04	33	14519	31062	79698774
Uterine cancer	29.16	13.04	14	14538	3677	79726159
Drug ineffective	28.30	13.04	102	14450	1080811	78649025
Bone pain	26.36	13.04	41	14511	55701	79674135
Oedema peripheral	26.09	13.04	103	14449	252185	79477651
Feeling abnormal	25.26	13.04	75	14477	159124	79570712
Cerebral infarction	25.03	13.04	36	14516	45640	79684196
Completed suicide	23.10	13.04	8	14544	245759	79484077
Infusion related reaction	22.51	13.04	7	14545	230230	79499606
Hyperlipidaemia	21.23	13.04	25	14527	26068	79703768
Product use issue	21.20	13.04	6	14546	209816	79520020
Blindness unilateral	21.17	13.04	15	14537	8131	79721705
Death	21.07	13.04	45	14507	566469	79163367
Cataract	20.55	13.04	39	14513	62081	79667755
Myocardial infarction	20.52	13.04	77	14475	184052	79545784
Low turnover osteopathy	20.28	13.04	9	14543	1977	79727859
Blood calcium increased	20.02	13.04	16	14536	10384	79719452
Back pain	19.49	13.04	108	14444	304072	79425764
Ischaemic stroke	19.47	13.04	27	14525	33104	79696732
Diverticulum	18.75	13.04	18	14534	14878	79714958
Fractured sacrum	18.57	13.04	8	14544	1635	79728201
Intentional product use issue	18.10	13.04	3	14549	152109	79577727
Intestinal pseudo-obstruction	17.93	13.04	9	14543	2600	79727236
Intervertebral disc degeneration	17.87	13.04	18	14534	15767	79714069
Endometrial hyperplasia	17.79	13.04	6	14546	630	79729206
Injection site erythema	17.64	13.04	42	14510	78155	79651681
General physical health deterioration	17.14	13.04	15	14537	275223	79454613
Atrophic vulvovaginitis	17.14	13.04	7	14545	1254	79728582
Uterine leiomyoma	17.06	13.04	12	14540	6431	79723405
Stress fracture	16.99	13.04	12	14540	6468	79723368
Treatment failure	16.99	13.04	5	14547	170481	79559355
Drug intolerance	16.93	13.04	14	14538	264105	79465731
Retinal haemorrhage	16.58	13.04	13	14539	8204	79721632
Insulinoma	16.47	13.04	4	14548	128	79729708
Femoral neck fracture	16.38	13.04	14	14538	9970	79719866
Foot fracture	16.15	13.04	20	14532	21961	79707875
Synovitis	15.81	13.04	4	14548	150730	79579106
Acute kidney injury	15.61	13.04	46	14506	519358	79210478
Osteomyelitis	15.29	13.04	24	14528	32841	79696995
Rib fracture	15.27	13.04	22	14530	27925	79701911
Product use in unapproved indication	15.16	13.04	14	14538	250345	79479491
Endometrial hypertrophy	15.16	13.04	4	14548	180	79729656
Dementia Alzheimer's type	15.03	13.04	6	14546	1013	79728823
Jaw disorder	14.85	13.04	10	14542	4996	79724840
Erythema multiforme	14.51	13.04	17	14535	17634	79712202
Therapeutic product effect incomplete	14.40	13.04	4	14548	141641	79588195
Tibia fracture	14.23	13.04	10	14542	5351	79724485
Vascular headache	14.17	13.04	3	14549	51	79729785
Breast cancer recurrent	14.06	13.04	8	14544	2969	79726867
Osteoporotic fracture	13.86	13.04	9	14543	4231	79725605
Benign vulval neoplasm	13.75	13.04	3	14549	59	79729777
Fibrocystic breast disease	13.68	13.04	5	14547	665	79729171
Bone disorder	13.42	13.04	17	14535	19096	79710740
Breast swelling	13.28	13.04	6	14546	1374	79728462
Thrombotic stroke	13.12	13.04	5	14547	746	79729090

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03XC01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Selective estrogen receptor modulators
FDA MoA	N0000000168	Selective Estrogen Receptor Modulators
CHEBI has role	CHEBI:50646	antiosteoporotic
CHEBI has role	CHEBI:50837	oestrogen antagonist
FDA EPC	N0000175826	Estrogen Agonist/Antagonist
MeSH PA	D050071	Bone Density Conservation Agents
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D020847	Estrogen Receptor Modulators
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D020845	Selective Estrogen Receptor Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postmenopausal osteoporosis	indication	102447009
Prevention of Breast Carcinoma	indication
Prevention of Glucocorticoid-Induced Osteoporosis	off-label use
Lupus anticoagulant disorder	contraindication	19267009
Hypertensive disorder	contraindication	38341003	DOID:10763
Thrombosis of retinal vein	contraindication	46085004
Chronic heart failure	contraindication	48447003
Atrial fibrillation	contraindication	49436004	DOID:0060224
Thrombophlebitis	contraindication	64156001	DOID:3875
Deep venous thrombosis	contraindication	128053003
Impaired renal function disorder	contraindication	197663003
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.13	acidic
pKa2	8.6	acidic
pKa3	9.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN	MODULATOR	EC50	8	WOMBAT-PK	CHEMBL
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	ANTAGONIST	IC50	9.40	WOMBAT-PK	IUPHAR
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.41	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.93	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.21	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.42	CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	9	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.72	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.55	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.38	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.16	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.21	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.30	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.77	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.28	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	8.54	WOMBAT-PK
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	6.52	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.97	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.83	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		EC50	4.93	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.32	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	6.19	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.63	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	6.40	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5.70	DRUG MATRIX
G-protein coupled estrogen receptor 1	GPCR	Q99527	GPER1_HUMAN		EC50	6.50	WOMBAT-PK
Interleukin-6	Cytokine	P05231	IL6_HUMAN		IC50	8.05	WOMBAT-PK
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.44	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	4.94	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.88	DRUG MATRIX
Phospholipase D1	Enzyme	Q13393	PLD1_HUMAN		IC50	5.40	CHEMBL
Phospholipase D2	Enzyme	O14939	PLD2_HUMAN		IC50	5.47	CHEMBL
Lysine-specific histone demethylase 1A	Enzyme	O60341	KDM1A_HUMAN		IC50	5.68	CHEMBL
Complement C5	Secreted	P01031	CO5_HUMAN		Kd	6.15	CHEMBL
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.32	DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain	Unclassified	P04439	1A03_HUMAN		Kd	4.66	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.71	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.83	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	6.07	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.63	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	5.66	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT		Ki	9.43	CHEMBL
Estrogen receptor beta	Transcription factor		ESR2_RAT		Ki	8.56	CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	7.18	CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	4.48	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT ESR2_RAT		IC50	8.73	CHEMBL

External reference:

ID	Source
4024098	VUID
N0000022103	NUI
D02217	KEGG_DRUG
82640-04-8	SECONDARY_CAS_RN
4021080	VANDF
4024098	VANDF
C0244404	UMLSCUI
CHEBI:8772	CHEBI
RAL	PDB_CHEM_ID
CHEMBL81	ChEMBL_ID
CHEMBL1116	ChEMBL_ID
D020849	MESH_DESCRIPTOR_UI
DB00481	DRUGBANK_ID
2820	IUPHAR_LIGAND_ID
5388	INN_ID
YX9162EO3I	UNII
5035	PUBCHEM_CID
166551	RXNORM
11500	MMSL
5410	MMSL
83711	MMSL
d04261	MMSL
007282	NDDF
007283	NDDF
109029006	SNOMEDCT_US
395856004	SNOMEDCT_US
419530003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7290	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7290	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5295	TABLET, FILM COATED	60 mg	ORAL	ANDA	20 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6902	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	16714-213	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	16714-213	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	31722-256	TABLET	60 mg	ORAL	ANDA	20 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-726	TABLET, FILM COATED	60 mg	ORAL	ANDA	31 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	43353-253	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43598-505	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43598-505	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3363	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3866	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5458	TABLET	60 mg	ORAL	ANDA	27 sections
Raloxifene hydrochloride	Human Prescription Drug Label	1	50090-6177	TABLET, COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50228-306	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50228-306	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-694	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4170	TABLET	60 mg	ORAL	NDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	60687-266	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	60687-266	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7708	TABLET	60 mg	ORAL	ANDA	27 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8209	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	65862-709	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections